Percutaneous coronary intervention-lobectomy for Lung Cancer hybrid surgery: an initial case series
Abstract Background For patients diagnosed with both lung cancer and severe coronary heart disease (CHD), the conflict between revascularization and lung cancer surgery remains to be settled to balance how to attenuate the cardiovascular risk for lung surgery and shorten the waiting time of anti-pla...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Cardio-Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40959-025-00317-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850190719448252416 |
|---|---|
| author | Jing Zeng Junyi Yu Qiao Mei Ye Yuan Taiming Zhang Longyong Mei Lingling Huang Yijie Hu Bo Deng Gengze Wu Chunyu Zeng |
| author_facet | Jing Zeng Junyi Yu Qiao Mei Ye Yuan Taiming Zhang Longyong Mei Lingling Huang Yijie Hu Bo Deng Gengze Wu Chunyu Zeng |
| author_sort | Jing Zeng |
| collection | DOAJ |
| description | Abstract Background For patients diagnosed with both lung cancer and severe coronary heart disease (CHD), the conflict between revascularization and lung cancer surgery remains to be settled to balance how to attenuate the cardiovascular risk for lung surgery and shorten the waiting time of anti-platelet therapy after revascularization. This study presents the percutaneous coronary intervention (PCI)-lobectomy for lung cancer hybrid surgery (PLHS), and its antithrombotic therapeutic strategy. Methods From October 2020 to June 2023, 14 patients, with unstable angina and resectable lung cancer received PLHS. All procedures were performed in a hybrid operating room. Drug-eluting stents (DES) were implanted during PCI. Lobectomy was carried out within one hour after PCI. Results Procedural success was 100%. All the patients subjected to PLHS were alive after 12 months of follow-up; 2 patients (14.29%) died due to distant metastasis within 12–24 months post-PLHS. There were no intraoperative complications, or 30-day- and 3-month-mortality. Except for one patient who suffered pneumothorax, no other postoperative complications, including severe bleeding, or in-stent restenosis, occurred in the 31.7 ± 10.9 months follow-up. Conclusions PLHS is a feasible and potentially safe option for patients with both lung cancer and severe CHD. |
| format | Article |
| id | doaj-art-43989dbf86ae4a85903f1f200ab2f19a |
| institution | OA Journals |
| issn | 2057-3804 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardio-Oncology |
| spelling | doaj-art-43989dbf86ae4a85903f1f200ab2f19a2025-08-20T02:15:11ZengBMCCardio-Oncology2057-38042025-02-011111810.1186/s40959-025-00317-6Percutaneous coronary intervention-lobectomy for Lung Cancer hybrid surgery: an initial case seriesJing Zeng0Junyi Yu1Qiao Mei2Ye Yuan3Taiming Zhang4Longyong Mei5Lingling Huang6Yijie Hu7Bo Deng8Gengze Wu9Chunyu Zeng10Department of Cardiology, Daping Hospital, The Third Military Medical University (Army Medical University)Department of Cardiology, Daping Hospital, The Third Military Medical University (Army Medical University)Department of Cardiology, Daping Hospital, The Third Military Medical University (Army Medical University)Department of Cardiovascular Surgery, Daping Hospital, The Third Military Medical University (Army Medical University)Department of Thoracic Surgery, Daping Hospital, The Third Military Medical University (Army Medical University)Department of Thoracic Surgery, Daping Hospital, The Third Military Medical University (Army Medical University)Department of Cardiology, Daping Hospital, The Third Military Medical University (Army Medical University)Key Laboratory of Geriatric Cardiovascular and Cerebrovascular Disease Research, Chongqing Key Laboratory for Hypertension Research, Chongqing Cardiovascular Clinical Research Center, Ministry of Education of China, Chongqing Institute of CardiologyDepartment of Thoracic Surgery, Daping Hospital, The Third Military Medical University (Army Medical University)Department of Cardiology, Daping Hospital, The Third Military Medical University (Army Medical University)Department of Cardiology, Daping Hospital, The Third Military Medical University (Army Medical University)Abstract Background For patients diagnosed with both lung cancer and severe coronary heart disease (CHD), the conflict between revascularization and lung cancer surgery remains to be settled to balance how to attenuate the cardiovascular risk for lung surgery and shorten the waiting time of anti-platelet therapy after revascularization. This study presents the percutaneous coronary intervention (PCI)-lobectomy for lung cancer hybrid surgery (PLHS), and its antithrombotic therapeutic strategy. Methods From October 2020 to June 2023, 14 patients, with unstable angina and resectable lung cancer received PLHS. All procedures were performed in a hybrid operating room. Drug-eluting stents (DES) were implanted during PCI. Lobectomy was carried out within one hour after PCI. Results Procedural success was 100%. All the patients subjected to PLHS were alive after 12 months of follow-up; 2 patients (14.29%) died due to distant metastasis within 12–24 months post-PLHS. There were no intraoperative complications, or 30-day- and 3-month-mortality. Except for one patient who suffered pneumothorax, no other postoperative complications, including severe bleeding, or in-stent restenosis, occurred in the 31.7 ± 10.9 months follow-up. Conclusions PLHS is a feasible and potentially safe option for patients with both lung cancer and severe CHD.https://doi.org/10.1186/s40959-025-00317-6Coronary heart diseaseLung cancerPercutaneous coronary interventionLobectomyAntithrombotic therapy |
| spellingShingle | Jing Zeng Junyi Yu Qiao Mei Ye Yuan Taiming Zhang Longyong Mei Lingling Huang Yijie Hu Bo Deng Gengze Wu Chunyu Zeng Percutaneous coronary intervention-lobectomy for Lung Cancer hybrid surgery: an initial case series Cardio-Oncology Coronary heart disease Lung cancer Percutaneous coronary intervention Lobectomy Antithrombotic therapy |
| title | Percutaneous coronary intervention-lobectomy for Lung Cancer hybrid surgery: an initial case series |
| title_full | Percutaneous coronary intervention-lobectomy for Lung Cancer hybrid surgery: an initial case series |
| title_fullStr | Percutaneous coronary intervention-lobectomy for Lung Cancer hybrid surgery: an initial case series |
| title_full_unstemmed | Percutaneous coronary intervention-lobectomy for Lung Cancer hybrid surgery: an initial case series |
| title_short | Percutaneous coronary intervention-lobectomy for Lung Cancer hybrid surgery: an initial case series |
| title_sort | percutaneous coronary intervention lobectomy for lung cancer hybrid surgery an initial case series |
| topic | Coronary heart disease Lung cancer Percutaneous coronary intervention Lobectomy Antithrombotic therapy |
| url | https://doi.org/10.1186/s40959-025-00317-6 |
| work_keys_str_mv | AT jingzeng percutaneouscoronaryinterventionlobectomyforlungcancerhybridsurgeryaninitialcaseseries AT junyiyu percutaneouscoronaryinterventionlobectomyforlungcancerhybridsurgeryaninitialcaseseries AT qiaomei percutaneouscoronaryinterventionlobectomyforlungcancerhybridsurgeryaninitialcaseseries AT yeyuan percutaneouscoronaryinterventionlobectomyforlungcancerhybridsurgeryaninitialcaseseries AT taimingzhang percutaneouscoronaryinterventionlobectomyforlungcancerhybridsurgeryaninitialcaseseries AT longyongmei percutaneouscoronaryinterventionlobectomyforlungcancerhybridsurgeryaninitialcaseseries AT linglinghuang percutaneouscoronaryinterventionlobectomyforlungcancerhybridsurgeryaninitialcaseseries AT yijiehu percutaneouscoronaryinterventionlobectomyforlungcancerhybridsurgeryaninitialcaseseries AT bodeng percutaneouscoronaryinterventionlobectomyforlungcancerhybridsurgeryaninitialcaseseries AT gengzewu percutaneouscoronaryinterventionlobectomyforlungcancerhybridsurgeryaninitialcaseseries AT chunyuzeng percutaneouscoronaryinterventionlobectomyforlungcancerhybridsurgeryaninitialcaseseries |